Wound care gamechanger SolasCure wins £405k grant

The hydrogel, containing tarumase (provisional INN) – an enzyme cloned from medical maggots – is for the treatment of millions of patients worldwide with chronic wounds.

The grant will be used to improve the ambient temperature stability of Aurase Wound Gel enabling transport and use of the product in a wide range of settings, as well as to adjust the release kinetics to ensure that tarumase is present at the wound surface at optimal concentrations throughout the treatment period.

By optimizing Aurase Wound Gel for further clinical trials, SolasCure aims to deliver an innovative product that will promote the healing of chronic wounds by addressing all elements of wound management – one that is cost-effective, fast, efficacious, and pain-free, and that can be used easily in community or home care settings.

Andy Weymann, chair of the SolasCure board, said: “Chronic wounds represent an immense healthcare and economic burden. The Biomedical Catalyst grant award provides exciting validation and recognition from Innovate UK that SolasCure has the technical innovation to address this urgent unmet medical need.

“Following the landmark publication of our Phase IIa clinical trial data, the injection of this additional non-dilutive funding takes the development of Aurase Wound Gel one step closer to improving the lives of millions of patients suffering from chronic wounds.”

The Innovate UK funding complements a recently received European Innovation Council Accelerator grant to further de-risk SolasCure’s development of Aurase Wound Gel.